1. Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents
   Yang Chen et al, 2017 CrossRef
2. SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer.
   Karolin Eifler et al, 2015, Trends Biochem Sci CrossRef
3. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme–CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain
   Liberty François-Moutal et al, 2018, PAIN CrossRef
4. Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis
   Pei-Fang Hung et al, 2019, J Exp Clin Cancer Res CrossRef
5. SUMOylation in Glioblastoma: A Novel Therapeutic Target
   Brandon M. Fox et al, 2019, IJMS CrossRef
6. SUMO Rules: Regulatory Concepts and Their Implication in Neurologic Functions
   Mathias Droescher et al, 2013, Neuromol Med CrossRef
7. Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds.
   Gu He, 0 CrossRef
8. SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases
   Wei Yang et al, 2015, Proteomics CrossRef
9. Characterization of amino acid residues within the N-terminal region of Ubc9 that play a role in Ubc9 nuclear localization
   Palak Sekhri et al, 2015, Biochemical and Biophysical Research Communications CrossRef
10. SUMO pathway components as possible cancer biomarkers
    Domenico Mattoscio et al, 2015, Future Oncology CrossRef
11. Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer
    Xiaoke Liu et al, 2015, J Hematol Oncol CrossRef
12. SUMOylation of KLF4 acts as a switch in transcriptional programs that control VSMC proliferation
    Chan-juan Nie et al, 2016, Experimental Cell Research CrossRef
13. The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis
    null Dehnavi et al, 2019, JCM CrossRef
14. Delineating the HMGB1 and HMGB2 interactome in prostate and ovary epithelial cells and its relationship with cancer
    Aida Barreiro-Alonso et al, 2018, Oncotarget CrossRef
15. The RNA helicase A in malignant transformation
    Marco Fidaleo et al, 2016, Oncotarget CrossRef
16. UBE2I promotes metastasis and correlates with poor prognosis in hepatocellular carcinoma.
    Hao Yang et al, 2020, Cancer Cell Int CrossRef
17. Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma
    Toshihide Nishimura et al, 2020, Sci Rep CrossRef
18. The post-translational modification, SUMOylation, and cancer (Review).
    Zhi-Jian Han et al, 2018, Int J Oncol CrossRef
19. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs
    Guofang Hou et al, 2021 CrossRef
20. Ubiquitin-Conjugating Enzymes in Cancer.
    Quyen Thu Bui et al, 2021, Cells CrossRef
21. Dissecting multiple roles of SUMOylation in prostate cancer
    Yishu Wang et al, 2021, Cancer Letters CrossRef
22. Identification of UBE2I as a Novel Biomarker in ccRCC Based on a Large-Scale CRISPR-Cas9 Screening Database and Immunohistochemistry
    Feng Li et al, 2022, Front. Mol. Biosci. CrossRef
23. Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases
    Dexiang Hua et al, 2022, European Journal of Medicinal Chemistry CrossRef
24. The UBC9/SUMO pathway affects E-cadherin cleavage in HPV-positive head and neck cancer
    Maria Elisa Sabatini et al, 2022, Front. Mol. Biosci. CrossRef
25. PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation
    Luyao Wei et al, 2022, Oncogene CrossRef
26. SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression
    Jianjun Li et al, 2023, Mol Biomed CrossRef
27. A novel cell-permeable peptide prevents protein sumoylation and supports the mislocalization and aggregation of TDP-43
    R. Marino et al, 2023, Neurobiology of Disease CrossRef
28. The emerging roles of SUMOylation in pulmonary diseases
    Xuyang Zheng et al, 2023, Mol Med CrossRef
29. The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer
    Nicole E. Pellegrino et al, 2022, IJMS CrossRef
30. Crossing epigenetic frontiers: the intersection of novel histone modifications and diseases
    Weiyi Yao et al, 2024, Sig Transduct Target Ther CrossRef
31. UBE2Q1 as a novel cancer biomarker for lung adenocarcinoma
    Wei Jiang et al, 2024, The American Journal of the Medical Sciences CrossRef